Revolution Medicines’ daraxonrasib produced striking survival gains in RAS-driven metastatic pancreatic cancer, with detailed Phase 3 RASolute 302 results presented at ASCO and simultaneously published in The New England Journal of Medicine. In the broader population, daraxonrasib roughly halved the risk of death versus standard chemotherapy and delivered a median overall survival of 13.2 months. The benefit extended to patients with the RAS G12 mutation subset, where median survival was 6.6 months with chemotherapy compared with a markedly longer outcome for the targeted therapy arm. Investigators also reported improved disease-control timeframes, with median progression-free outcomes roughly doubling in the daraxonrasib-treated groups. Clinicians described the Kaplan-Meier curves as unprecedented for the second-line setting, and the results increase pressure on competitors to produce similarly differentiated follow-on data. The next developments to watch are consistency across mutation groups, duration of response, and how future trials incorporate daraxonrasib earlier in the disease course.